Royal Bank of Canada increased its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 8.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 28,263 shares of the medical research company’s stock after purchasing an additional 2,254 shares during the quarter. Royal Bank of Canada owned approximately 0.10% of Bio-Rad Laboratories worth $9,908,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. KBC Group NV purchased a new stake in shares of Bio-Rad Laboratories in the 4th quarter valued at $581,000. Panagora Asset Management Inc. raised its holdings in Bio-Rad Laboratories by 4.5% in the 4th quarter. Panagora Asset Management Inc. now owns 1,284 shares of the medical research company’s stock worth $475,000 after purchasing an additional 55 shares in the last quarter. Toronto Dominion Bank raised its holdings in Bio-Rad Laboratories by 43,166.7% in the 4th quarter. Toronto Dominion Bank now owns 3,894 shares of the medical research company’s stock worth $1,441,000 after purchasing an additional 3,885 shares in the last quarter. Advisors Asset Management Inc. raised its holdings in Bio-Rad Laboratories by 7.7% in the 1st quarter. Advisors Asset Management Inc. now owns 6,024 shares of the medical research company’s stock worth $2,112,000 after purchasing an additional 430 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Bio-Rad Laboratories by 2.4% in the 1st quarter. Geode Capital Management LLC now owns 248,937 shares of the medical research company’s stock worth $87,193,000 after purchasing an additional 5,951 shares in the last quarter. Institutional investors and hedge funds own 63.08% of the company’s stock.

Shares of BIO stock opened at $432.34 on Tuesday. Bio-Rad Laboratories, Inc. has a one year low of $303.82 and a one year high of $497.42. The company’s 50-day moving average is $460.77 and its 200 day moving average is $399.62. The company has a market capitalization of $12.82 billion, a price-to-earnings ratio of 8.28 and a beta of 1.08. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.76 and a current ratio of 2.40.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Wednesday, May 6th. The medical research company reported $1.91 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.57 by $0.34. Bio-Rad Laboratories had a net margin of 67.81% and a return on equity of 3.95%. The company had revenue of $571.60 million for the quarter, compared to the consensus estimate of $545.70 million. During the same period in the prior year, the firm posted $1.65 EPS. Bio-Rad Laboratories’s revenue for the quarter was up 3.2% on a year-over-year basis. As a group, research analysts predict that Bio-Rad Laboratories, Inc. will post 7.2 earnings per share for the current fiscal year.

Several research analysts recently issued reports on BIO shares. Citigroup increased their price target on shares of Bio-Rad Laboratories from $480.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Wells Fargo & Co increased their price target on shares of Bio-Rad Laboratories from $495.00 to $525.00 and gave the stock an “overweight” rating in a research note on Thursday, May 21st. Finally, Barclays decreased their price target on shares of Bio-Rad Laboratories from $435.00 to $430.00 and set an “overweight” rating for the company in a research note on Thursday, March 26th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Bio-Rad Laboratories currently has a consensus rating of “Buy” and a consensus price target of $470.00.

In other news, EVP Michael Crowley sold 1,500 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $485.40, for a total transaction of $728,100.00. Following the sale, the executive vice president now owns 2,310 shares of the company’s stock, valued at approximately $1,121,274. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Ronald W. Hutton sold 443 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $457.35, for a total transaction of $202,606.05. The disclosure for this sale can be found here. Corporate insiders own 27.50% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Further Reading: How are dividend achievers different from dividend aristocrats?

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.